Pre-Screening for A Phase Ia/Ib first-in-human clinical trial to evaluate the safety, tolerability and Initial anti-tumor activity of IMA401, a bispecific T cell engaging receptor molecule (TCER®), in patients with recurrent and/or refractory solid tumors
Laufzeit: 01.01.2021 - 31.12.2027
imported
Kurzfassung
Pre-Screening for A Phase Ia/Ib first-in-human clinical trial to evaluate the safety, tolerability and Initial anti-tumor activity of IMA401, a bispecific T cell engaging receptor molecule (TCER), in patients with recurrent and/or refractory solid tumors
Beteiligte Einrichtungen
